Rock Springs Capital LENZ Position
Active7-Fund ConvergenceRock Springs Capital increased their position in LENZ Therapeutics, Inc. (LENZ) in Q4 2025, holding $4.1M worth of shares across 257,460 shares.
The position was first reported in Q4 2024 and has been tracked across 5 quarterly 13F filings.
LENZ is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 52.7% of float with 13.3 days to cover, indicating significant bearish positioning against Rock Springs's long thesis.
3 insider purchases totaling $366K have been filed in the last 90 days, providing an additional conviction signal.
About LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Full company profile →Short Interest
52.7%
13.3 days to cover
Insider Buys (90d)
3
$366K total
Rock Springs Capital LENZ Position History
Frequently Asked Questions
Does Rock Springs Capital own LENZ?
Yes. As of Q4 2025, Rock Springs Capital holds 257,460 shares of LENZ Therapeutics, Inc. (LENZ) valued at $4.1M. This data comes from their SEC 13F filing.
How many hedge funds own LENZ?
7 specialist biotech hedge funds currently hold LENZ, including RA Capital Management, Tang Capital Management, RTW Investments and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy LENZ?
Rock Springs Capital's position in LENZ was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's LENZ position increasing or decreasing?
Rock Springs Capital increased their LENZ position in the most recent quarter, adding 21,233 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
LENZCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →